Allergan Plc Ordinary Shares (NYSE:AGN)’s Stock Is Sell After More Market Selling

April 17, 2018 - By Jeanette Kaplan

Allergan plc (NYSE:AGN) Logo

Investors sentiment increased to 1.25 in 2017 Q4. Its up 0.92, from 0.33 in 2017Q3. It increased, as 2 investors sold Allergan plc shares while 2 reduced holdings. 1 funds opened positions while 4 raised stakes. 44,210 shares or 18.56% less from 54,287 shares in 2017Q3 were reported.
Mitchell Mcleod Pugh & Williams accumulated 3,965 shares or 0.45% of the stock. Cubic Asset Mgmt Limited Liability Company holds 0.11% or 2,321 shares. Grassi Invest Mngmt stated it has 7,435 shares. Eqis Cap Management Inc stated it has 10,789 shares. American Research Mngmt owns 33 shares or 0% of their US portfolio. Moreover, Callahan Advsr has 0.15% invested in Allergan plc (NYSE:AGN) for 4,500 shares. Frontier Investment holds 14,953 shares or 0.2% of its portfolio. Gemmer Asset Management Ltd Liability invested 0.01% of its portfolio in Allergan plc (NYSE:AGN).

The stock of Allergan Plc Ordinary Shares (NYSE:AGN) registered an increase of 9.83% in short interest. AGN’s total short interest was 7.02 million shares in April as published by FINRA. Its up 9.83% from 6.39 million shares, reported previously. With 3.00M shares average volume, it will take short sellers 2 days to cover their AGN’s short positions. The short interest to Allergan Plc Ordinary Shares’s float is 2.23%.

The stock increased 0.64% or $1.06 during the last trading session, reaching $167.51. About 601,106 shares traded. Allergan plc (NYSE:AGN) has declined 33.03% since April 17, 2017 and is downtrending. It has underperformed by 44.58% the S&P500.

Allergan plc, a specialty pharmaceutical company, develops, makes, markets, and distributes medical aesthetics, biosimilar, and over-the-counter pharmaceutical products worldwide. The company has market cap of $54.87 billion. It operates through US Specialized Therapeutics, US General Medicine, and International divisions. It currently has negative earnings. The firm offers a portfolio of products that provide treatment for the central nervous system, gastroenterology, womenÂ’s health and urology, ophthalmology, neurosciences, medical aesthetics, dermatology, plastic surgery, liver disease, inflammation, metabolic syndromes, and fibrosis, as well as AlzheimerÂ’s disease.

Allergan plc (NYSE:AGN) Ratings Coverage

Among 18 analysts covering Allergan (NYSE:AGN), 13 have Buy rating, 0 Sell and 5 Hold. Therefore 72% are positive. Allergan had 32 analyst reports since October 18, 2017 according to SRatingsIntel. RBC Capital Markets maintained it with “Buy” rating and $221.0 target in Thursday, November 2 report. Barclays Capital upgraded the stock to “Overweight” rating in Monday, January 29 report. The stock of Allergan plc (NYSE:AGN) has “Hold” rating given on Tuesday, January 23 by Mizuho. The stock has “Buy” rating by Leerink Swann on Wednesday, February 7. The company was maintained on Wednesday, January 10 by UBS. The stock of Allergan plc (NYSE:AGN) earned “Buy” rating by Bank of America on Wednesday, February 7. Credit Suisse maintained Allergan plc (NYSE:AGN) rating on Monday, November 6. Credit Suisse has “Outperform” rating and $224 target. The stock of Allergan plc (NYSE:AGN) earned “Buy” rating by Credit Suisse on Thursday, March 1. Credit Suisse maintained Allergan plc (NYSE:AGN) on Tuesday, December 19 with “Buy” rating. The company was maintained on Thursday, October 19 by Citigroup.

Allergan plc (NYSE:AGN) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: